Overview

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Status:
Completed
Trial end date:
2019-01-18
Target enrollment:
0
Participant gender:
All
Summary
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Criteria
Inclusion Criteria:

- Have a diagnosis of migraine as defined by International Headache Society (IHS)
International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or
1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
screening, and migraine onset prior to age 50.

Exclusion Criteria:

- Are currently enrolled in or have participated within the last 30 days or within 5
half-lives (whichever is longer) in a clinical trial involving an investigational
product.

- Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its
receptor.

- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins, or to Galcanezumab and the excipients in the investigational product.

- History of persistent daily headache, cluster headache or migraine subtypes including
hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.